133 related articles for article (PubMed ID: 18710976)
1. Incidence of nephrogenic systemic fibrosis at two large medical centers.
Prince MR; Zhang H; Morris M; MacGregor JL; Grossman ME; Silberzweig J; DeLapaz RL; Lee HJ; Magro CM; Valeri AM
Radiology; 2008 Sep; 248(3):807-16. PubMed ID: 18710976
[TBL] [Abstract][Full Text] [Related]
2. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
Smorodinsky E; Ansdell DS; Foster ZW; Mazhar SM; Cruite I; Wolfson T; Sugay SB; Iussich G; Shiehmorteza M; Kono Y; Kuo A; Sirlin CB
J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
[TBL] [Abstract][Full Text] [Related]
3. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative.
Hoerger TJ; Simpson SA; Yarnoff BO; Pavkov ME; Ríos Burrows N; Saydah SH; Williams DE; Zhuo X
Am J Kidney Dis; 2015 Mar; 65(3):403-11. PubMed ID: 25468386
[TBL] [Abstract][Full Text] [Related]
4. Estimating prevalence of CKD stages 3-5 using health system data.
Shahinian VB; Hedgeman E; Gillespie BW; Young EW; Robinson B; Hsu CY; Plantinga LC; Burrows NR; Eggers P; Saydah S; Powe NR; Saran R;
Am J Kidney Dis; 2013 Jun; 61(6):930-8. PubMed ID: 23489675
[TBL] [Abstract][Full Text] [Related]
5. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
6. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
7. Type of MRI contrast, tissue gadolinium, and fibrosis.
Do C; Barnes JL; Tan C; Wagner B
Am J Physiol Renal Physiol; 2014 Oct; 307(7):F844-55. PubMed ID: 25100280
[TBL] [Abstract][Full Text] [Related]
8. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
10. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.
Attari H; Cao Y; Elmholdt TR; Zhao Y; Prince MR
Radiology; 2019 Aug; 292(2):376-386. PubMed ID: 31264946
[TBL] [Abstract][Full Text] [Related]
12. The feasibility of relaxation-enhanced angiography without contrast and triggering for preprocedural planning of transcatheter aortic valve implantation.
Wang R; Liu X; Yao J; Schoepf UJ; Griffith J; Wang J; Lian J; Jiang K; Song G; Xu L
Front Cardiovasc Med; 2023; 10():1284743. PubMed ID: 38179508
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager.
Gallo-Bernal S; Patino-Jaramillo N; Calixto CA; Higuera SA; Forero JF; Lara Fernandes J; Góngora C; Gee MS; Ghoshhajra B; Medina HM
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 36010167
[TBL] [Abstract][Full Text] [Related]
14. VHPKQHR Peptide Modified Ultrasmall Paramagnetic Iron Oxide Nanoparticles Targeting Rheumatoid Arthritis for T
Zhang C; Huang W; Huang C; Zhou C; Tang Y; Wei W; Li Y; Tang Y; Luo Y; Zhou Q; Chen W
Front Bioeng Biotechnol; 2022; 10():821256. PubMed ID: 35295653
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.
Davies J; Siebenhandl-Wolff P; Tranquart F; Jones P; Evans P
Arch Toxicol; 2022 Feb; 96(2):403-429. PubMed ID: 34997254
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic systemic fibrosis: A frivolous entity.
Bhargava V; Singh K; Meena P; Sanyal R
World J Nephrol; 2021 May; 10(3):29-36. PubMed ID: 34136369
[TBL] [Abstract][Full Text] [Related]
17. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
[TBL] [Abstract][Full Text] [Related]
18. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.
Tseng TY; Tseng JH; Huang BS; Lin SY; Chen CB; Fang YW; Lin G; Lai YC
Abdom Radiol (NY); 2021 Aug; 46(8):3995-4001. PubMed ID: 33742216
[TBL] [Abstract][Full Text] [Related]
19. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.
Weinreb JC; Rodby RA; Yee J; Wang CL; Fine D; McDonald RJ; Perazella MA; Dillman JR; Davenport MS
Kidney Med; 2021; 3(1):142-150. PubMed ID: 33604544
[TBL] [Abstract][Full Text] [Related]
20. Complex Metal Ions: Neuropsychiatric and Imaging Features.
Bateman JR; Taber KH; Hurley RA
J Neuropsychiatry Clin Neurosci; 2020; 32(4):A4-321. PubMed ID: 33118851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
